Value of the systemic immune-inflammation index in predicting poor postoperative outcomes and the short-term prognosis of heart valve diseases: a retrospective cohort study

Objective Systemic immune-inflammation index (SII) is a novel biomarker that can predict poor outcomes in tumours, nervous system diseases and chronic heart failure. Here, we investigated the predictive value of SII on the poor postoperative outcomes and short-term prognosis of heart valve diseases (HVDs). Design, setting and participants This retrospective cohort study enrolled all consecutive patients with HVDs (aortic stenosis, aortic regurgitation, mitral stenosis and mitral regurgitation) who underwent surgery (valve replacement or valve repair) at the Affiliated Hospital of North Sichuan Medical College between 2017 and 2020. Main outcomes and measures Major complications in the perioperative period, all-cause mortality within 30 days and readmission within 30 days. Results A total of 431 patients with HVDs were enrolled in this study, including 202 males and 229 females, aged 58.9±27.3 years. SII levels of patients in the poor outcomes group were significantly higher than those of patients in the favourable outcomes group (658.40±436.29 vs 335.72±174.76, respectively; p<0.001). Multivariate logistic regression analysis showed that age (OR 1.064, 95% CI 1.026 to 1.104, p=0.025), SII (OR 1.034, 95% CI 1.012 to 1.631, p=0.008) and aortic cross-clamping time (OR 1.013, 95% CI 1.004 to 1.023, p=0.006) were independent risk factors for poor outcomes and short-term prognosis in patients with HVD. The area under the curve of poor outcomes predicted by SII in patients with HVD was 0.806 (95% CI 0.763 to 0.848) and the optimised cut-off value 423.8×109 /L, with a sensitivity of 70.3% and specificity of 81.1%. The incidence of poor outcomes (p<0.001), 30-day mortality (p<0.001) and 30-day readmission rate (p=0.026) in the high SII group was significantly higher than that in the low SII group. Conclusions SII is closely related to poor postoperative outcomes and short-term prognosis of HVD and can serve as an independent predictive factor.

[1]  Wenchen Li,et al.  Predictive Value of the Systemic Immune Inflammation Index for Adverse Outcomes in Patients With Acute Ischemic Stroke , 2022, Frontiers in Neurology.

[2]  X. Kong,et al.  The Systemic Immune-Inflammation Index is an Independent Predictor of Survival in Breast Cancer Patients , 2022, Cancer management and research.

[3]  A. Tekkeşin,et al.  Evaluating systemic immune‐inflammation index in patients with implantable cardioverter defibrillator for heart failure with reduced ejection fraction , 2022, Pacing and clinical electrophysiology : PACE.

[4]  Tao Jiang,et al.  Predictive Value of Systemic Immune-Inflammation index and Neutrophil-to-Lymphocyte Ratio in Patients with Severe COVID-19 , 2022, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[5]  R. Bellomo,et al.  Renal and Cerebral Hypoxia and Inflammation During Cardiopulmonary Bypass. , 2021, Comprehensive Physiology.

[6]  Zheng Zhang,et al.  Higher Systemic Immune-Inflammation Index is associated with higher likelihood of peripheral arterial disease. , 2021, Annals of vascular surgery.

[7]  S. Doğan,et al.  Predictive Value of Systemic Immune Inflammation Index for Postoperative Atrial Fibrillation in Patients Undergoing Isolated Coronary Artery Bypass Grafting , 2021, Medeniyet medical journal.

[8]  C. Hengstenberg,et al.  Relevance of Neutrophil Neprilysin in Heart Failure , 2021, Cells.

[9]  M. Kaplan,et al.  Evaluation of N/LP Ratio as a Predictor of Disease Progression and Mortality in COVID-19 Patients Admitted to the Intensive Care Unit , 2021, Medeniyet medical journal.

[10]  H. Corominas,et al.  Valve Abnormalities, Risk Factors for Heart Valve Disease and Valve Replacement Surgery in Spondyloarthritis. A Systematic Review of the Literature , 2021, Frontiers in Cardiovascular Medicine.

[11]  Y. Ahn,et al.  Systemic Immune-Inflammation Index Predicted Short-Term Outcomes in Patients Undergoing Isolated Tricuspid Valve Surgery , 2021, Journal of clinical medicine.

[12]  F. Crea,et al.  Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases , 2021, Expert review of hematology.

[13]  S. Cakal,et al.  Prognostic Value of Systemic Immune-Inflammation Index for Major Adverse Cardiac Events and Mortality in Severe Aortic Stenosis Patients after TAVI , 2021, Medicina.

[14]  E. Kızıltunç,et al.  Relationship Between Systemic Immune-Inflammation Index (SII) and the Severity of Stable Coronary Artery Disease , 2021, Angiology.

[15]  Shiren Sun,et al.  Time to peak bilirubin concentration and advanced AKI were associated with increased mortality in rheumatic heart valve replacement surgery patients with severe postoperative hyperbilirubinemia: a retrospective cohort study , 2021, BMC Cardiovascular Disorders.

[16]  Yushen Wu,et al.  Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis , 2020, Cancer Cell International.

[17]  V. Grover,et al.  Systemic Immune-Inflammation Index Predicts Poor Outcome After Elective Off-Pump CABG: A Retrospective, Single-Center Study. , 2020, Journal of cardiothoracic and vascular anesthesia.

[18]  M. Weigand,et al.  Preoperative neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are associated with major adverse cardiovascular and cerebrovascular events in coronary heart disease patients undergoing non-cardiac surgery , 2020, BMC Cardiovascular Disorders.

[19]  M. Erturk,et al.  Systemic immune-inflammation index predicts mortality in infective endocarditis , 2019, Journal of the Saudi Heart Association.

[20]  N. Bragazzi,et al.  A systematic review of the cost-effectiveness of heart valve replacement with a mechanical versus biological prosthesis in patients with heart valvular disease , 2019, Heart Failure Reviews.

[21]  K. Sliwa,et al.  Genetics of rheumatic fever and rheumatic heart disease , 2019, Nature Reviews Cardiology.

[22]  M. Duran,et al.  Risk factors for coronary artery disease in young patients with stable angina pectoris , 2019, Turkish journal of medical sciences.

[23]  T. Lüscher,et al.  Novel findings in neutrophil biology and their impact on cardiovascular disease. , 2019, Cardiovascular research.

[24]  J. Sluijter,et al.  Lymphocytic subsets play distinct roles in heart diseases , 2019, Theranostics.

[25]  D. Missiakas,et al.  Staphylococcus aureus endocarditis: distinct mechanisms of bacterial adhesion to damaged and inflamed heart valves. , 2019, European heart journal.

[26]  C. Belziti,et al.  Neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio as predictors of survival after heart transplantation , 2017, ESC Heart Failure.

[27]  F. Fernández‐Avilés,et al.  Patients with calcific aortic stenosis exhibit systemic molecular evidence of ischemia, enhanced coagulation, oxidative stress and impaired cholesterol transport. , 2016, International journal of cardiology.

[28]  S. Epelman,et al.  Chronic Heart Failure and Inflammation: What Do We Really Know? , 2016, Circulation research.

[29]  M. Kurabayashi,et al.  Lipoprotein(a) is a risk factor for aortic and mitral valvular stenosis in peripheral arterial disease. , 2016, European heart journal cardiovascular Imaging.

[30]  A. Hoeft,et al.  Standards for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine: European Perioperative Clinical Outcome (EPCO) definitions A statement from the ESA-ESICM joint taskforce on perioperative outcome measures , 2015, European journal of anaesthesiology.

[31]  N. Kleiman,et al.  Association of immature platelets with adverse cardiovascular outcomes. , 2014, Journal of the American College of Cardiology.

[32]  Alec Vahanian,et al.  Epidemiology of acquired valvular heart disease. , 2014, The Canadian journal of cardiology.